Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12093187 | 0.83 | SLC6A4 (0.44) | SLC6A4SLC6A2KCNH2SLC6A3KDM1A | |
| SCHEMBL22105815 | 0.81 | SLC6A2 (0.41) | SLC6A4SLC6A2KCNH2 | |
| SCHEMBL12093083 | 0.80 | KCNH2 (0.44) | SLC6A4SLC6A2KCNH2SLC6A3KDM1A | |
| SCHEMBL22547322 | 0.77 | MCHR1 (0.44) | SLC6A4SLC6A2KCNH2 | |
| SCHEMBL12093188 | 0.76 | KCNH2 (0.39) | SLC6A4SLC6A2KCNH2KDM1A | |
| SCHEMBL17123794 | 0.76 | SLC6A2 (0.49) | SLC6A4SLC6A2KCNH2SLC6A3 | |
| Hydrochloric Acid SCHEMBL14861970 | 0.75 | SLC6A2 (0.47) | SLC6A4SLC6A2KCNH2SLC6A3 | |
| SCHEMBL14873937 | 0.73 | DRD4 (0.38) | SLC6A4SLC6A2KCNH2 | |
| SCHEMBL22547907 | 0.73 | KCNH2 (0.36) | SLC6A4SLC6A2KCNH2 | |
| SCHEMBL12093052 | 0.72 | NAAA (0.44) | SLC6A4SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | SLC6A4 3419/4885SLC6A2 2458/4885KCNH2 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.